nature immunology r e s o u r c e Systematic analyses of lymphocyte transcriptomes have yielded important insights about lymphocytes 1 . However, changes in the rates of protein synthesis and protein turnover create discordances between transcriptomes and proteomes 2,3 , and there is a need for quantitative proteomics mapping of cellular protein signatures for full definition of cell identity 4, 5 . In this context, the serine-threonine kinase mTORC1 ('mammalian target of rapamycin complex 1'), controls mRNA translation and protein degradation and controls the differentiation of CD8 + cytotoxic T lymphocytes (CTLs) [6] [7] [8] . mTORC1 has two known substrates in T cells: the kinase S6K1 and the translationinitiation inhibitor 4E-BP1, molecules that regulate protein production 9 . Moreover, one role of mTORC1 is to control the translation of mRNAs with 5′-terminal oligopyrimidine motifs that encode ribosomal proteins and translation factors to globally enhance cellular proteinsynthetic capacity 10 . Understanding mTORC1 function in CTLs thus requires an understanding of how mTORC1 controls proteomes. For example, published studies have shown mTORC1's translational control of the sterol regulatory element-binding proteins SREBP1 and SREBP2, which mediate the expression of sterol-biosynthesis enzymes 11,12 . mTORC1's translational control of the HIF1 transcription factor complex also directs the expression of glucose transporters, glycolytic enzymes and cytolytic effector molecules in CTLs 13 . The relevance of proteomics in understanding the effect of mTORC1 in CTLs also stems from the ability of mTORC1 to promote protein degradation. There are thus examples in other cell lineages in which mTORC1 regulates the phosphorylation of adaptors such as GRB10, IRS1 or IRS2 and modulates the degradation rates of these proteins [14] [15] [16] .
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A comprehensive analysis of mTORC1 control of T cell proteomes would thus directly inform how mTORC1 controls T cell biology. Accordingly, we have used high-resolution mass spectrometry (MS) to map the proteome of CTLs and to quantify the regulatory effect of selective inhibition of mTORC1 and combined inhibition of mTORC1 and mTORC2 on CTL proteomes. We demonstrated the diversity of the CTL proteome and how mTOR inhibitors control T cell function and program T cell signal-transduction pathways.
RESULTS
The CTL proteome High-resolution MS characterized the proteome of P14 CTLs (which have transgenic expression of a T cell antigen receptor specific for an epitope of lymphocytic choriomeningitis virus glycoprotein) ( Supplementary Fig. 1 ) and identified more than 93,000 peptides from 6,800 protein groups in these cells (Fig. 1a) . Summed peptide intensities derived from peak areas of ion-extracted MS chromatograms measure relative protein abundance when divided by the theoretically observable numbers of peptides and yield iBAQ ('intensity-based absolute quantification') intensities 2, 5 and can be transformed into absolute quantification by proteomic ruler methodology 17 . Copy numbers for proteins from three biological replicates showed strong Pearson correlation coefficients (0.86-0.89), with very few outliers and with ~94% of all proteins detected in all three biological replicates (Fig. 1b) ; this indicated the robustness and reproducibility of our MS-based peptide quantitation methods.
Proteomic data revealed protein abundance and specific protein isoforms or orthologs, which created an objective description of cell identity. We ranked CTL proteins by estimated copy number and plotted this against cumulative protein copy number. Proteins showed a wide range of expression spanning over seven orders of magnitude (Fig. 1c) . 12 proteins constituted 25% of the CTL protein mass; 249 proteins constituted 75% of the total CTL mass; and 6,579 proteins contributed to the remaining 25% of the CTL mass (Fig. 1c) . The 20 most abundant CTL proteins constituted nearly a third of all proteins and included histones and the cytoskeleton components vimentin and cofilin, as well as translational machinery proteins, ribosomal proteins, initiation and elongation factors ( Table 1) . The CTL effector molecule granzyme B and multiple glycolytic enzymes were also in this 'top 20' list ( Table 1) , and the quartile of the CTL proteome with highest intensity showed enrichment for pathways involved in metabolism and macromolecular biosynthesis (Fig. 1c) compared with the abundance of these proteins in the whole data set. As CD8 + T cells differentiate into CTLs, they switch from metabolizing glucose mainly through oxidative phosphorylation to using the glycolytic pathway 18 . The proteomic data showed that much of the CTL protein mass was dedicated to glycolysis, although CTLs retained abundant amounts of the protein machinery for oxidative phosphorylation (Fig. 1c) , which suggested that it might be important for them to retain flexibility in terms of their metabolic strategy for glucose metabolism.
The proteomic data revealed new insight into the expression of protein isoforms and orthologs in T cells. For example, CTLs expressed multiple nutrient transporters, but, in terms of abundance, the amino acid transporter SLC7A5 and its dimer partner SLC3A2 predominated (Fig. 2a) . This finding would explain why deletion of SLC7A5 has such a severely deleterious effect on CTL function 19 . Glucose transport is important for CTLs 20 , and published studies have focused on the glucose transporter GLUT1 in T cells 21 . We found that GLUT3, which has a higher glucose transport capacity than that of GLUT1 (ref. 22) , was expressed in amounts equivalent to those of GLUT1 in CTLs (Fig. 2a) . Deletion of GLUT1 affects T cell function 21 , but the presence of GLUT3 explains why loss of GLUT1 is not catastrophic.
We also used proteomic ruler methodology 17 to estimate absolute protein copy numbers to quantify the key cytokine receptors, transcription factors and effector molecules that define CTL identity. Granzymes A and B were present in high copy numbers in CTLs (4.9 × 10 6 and 2.2 × 10 7 , respectively; Fig. 2b ), which would explain how CTLs can rapidly kill multiple targets. We observed a wide range in the copy number of transcription factors: the copy numbers of STAT1, STAT3 and STAT5 were higher (1 × 10 4 to 1 × 10 5 ) than those of T-bet, Foxo1, Foxo3, EOMES, STAT4 or STAT6 (1 × 10 3 to 1 × 10 4 ) (Fig. 2c) . The higher copy number of antigen receptor-coupled tyrosine kinases Lck and Zap70 than that of cytokine receptor-coupled kinases JAK1, JAK3 and TYK2 was notable (Fig. 2d) . The tyrosine phosphatases CD45 and r e s o u r c e npg r e s o u r c e SHP-1 were expressed at an abundance similar to that of these tyrosine kinases (Fig. 2d) , indicative of the importance of negative regulators in intracellular signaling networks. The data also revealed the stoichiometry of cytokine receptor subunits. For example, interleukin 2 (IL-2) signals to T cells via a high-affinity receptor comprising CD25 (IL-2 receptor α-chain), CD122 (IL-2 receptor β-subunit (IL-2RB)) and CD132 (the common γ-chain (γ c )). CTLs expressed approximately ~100-fold more copies of CD25 than of IL-2RB or γ c (Fig. 2e) . Published studies have reported an excess of CD25 relative to the number of highaffinity IL-2 receptor complexes on CTL membranes 23 , and an excess of CD25 over IL-2RB has been quantified by flow cytometry 24 . Our data revealed that the abundance of IL-2RB and γ c was limiting at approximately 1 × 10 4 copies of IL-2RB per cell and 2 × 10 4 to 3 × 10 4 copies of γ c per cell (Fig. 2e) IL-2RB and γ c bind to JAK1 and JAK3, respectively, and the copy number of these kinases was broadly equivalent to that of IL-2RB and γ c (Fig. 2e) , which indicated that formation of the high-affinity IL-2 receptor in CTLs would be limited by availability of IL-2RB and γ c and their associated tyrosine kinases. These examples all illustrate how understanding protein copy number can afford new insight into cell identity and cellular control mechanisms.
Comparison of the CTL transcriptome and proteome Systematic analysis of transcriptomes has yielded critical insight into how T cells direct adaptive immune responses 25 . We assessed whether proteomic data provided additional insight by correlating estimated protein copy numbers in CTLs with the transcript intensities of corresponding mRNA by using the probe intensities derived from a parallel Affymetrix microarray data set (Fig. 3a) . The rather moderate positive correlation between mRNA abundance and protein abundance, with a coefficient of determination of 0.43 ( Fig. 3a) , indicated that post-transcriptional regulatory mechanisms substantially affected the CTL proteome. Examples of discordance between mRNA abundance and protein abundance included the finding that CTLs had comparable expression of T-bet mRNA and EOMES mRNA, whereas T-bet protein was much more abundant than EOMES protein (Fig. 3b) . In a second example, the ratio for the IL-2 receptor subunits estimated from transcript intensity was 3:1:2 (α:β:γ), whereas the corresponding ratio for protein intensity was 92:1:2 (Fig. 3c) . There was close correspondence between transcript abundance and protein abundance for some proteins, such as ribosomal proteins and granzymes ( Fig. 3d,e) . Nevertheless, these data highlighted the importance of direct measurement of the protein, rather than measurement of the mRNA as a surrogate, for estimation of protein expression.
Selective programming of the CTL proteome by mTORC1
CTLs had high mTORC1 activity, as judged by phosphorylation of the mTORC1 substrates S6K1 (at Thr389) and 4E-BP1 (at Ser37 and Ser46 and at Ser65) (Fig. 4a) . Treatment of CTLs with the mTORC1 inhibitor rapamycin caused dephosphorylation of these two substrates. mTOR exists in two protein complexes, mTORC1 and mTORC2, that are defined by their scaffolding and regulatory components. CTLs had high activity of mTORC2, as judged by phosphorylation of the mTORC2 substrate Akt at Ser473. Treatment with rapamycin did not cause dephosphorylation of Akt at Ser473. In contrast, the mTOR catalytic inhibitor KU-0063794, which blocks the activity of both mTORC1 and mTORC2 (ref. 26) , caused dephosphorylation of Akt at Ser473 and of Ser6K1 at Thr389, as well as dephosphorylation of 4E-BP1. Treatment with rapamycin decreased protein synthesis in CTLs over a 24-to 48-hour period and decreased the size and protein content CTLs (Fig. 4b,c) . We next used quantitative MS to assess whether inhibition of mTORC1 caused a small reduction in the abundance of all proteins or targeted a protein subset. We treated CTLs with the vehicle dimethyl sulfoxide (DMSO) or rapamycin and analyzed the cells at a single time point of 48 h to assess the sustained effect of inhibiting (Fig. 4d) . Notably, inhibition of mTORC1 decreased the expression of various CTL effector molecules, including granzymes, perforin, tumor-necrosis factor and interferon-γ (IFN-γ) (Fig. 4e) . The decrease in IFN-γ expression in rapamycin-treated CTLs was confirmed by enzyme-linked immunosorbent assay (ELISA) (Fig. 4f) . Published studies have reported that mTORC1 controls IFN-γ by controlling expression of T-bet 27 . We found no difference between untreated cells and rapamycin-treated cells in their T-bet expression, by MS or immunoblot analysis (Fig. 4g) . Notably, expression of CD62L (L-selectin), an adhesion molecule that controls the trafficking of T cells into secondary lymphoid tissues, was upregulated substantially in rapamycin-treated CTLs (Fig. 4d) , a result confirmed by ELISA (Fig. 4h) . Studies of non-lymphoid cells have reported mTORC1-induced degradation of the adaptors GRB10 (refs. 14,15) and IRS1 and IRS2 (ref. 16 ). GRB10 and IRS1 were not detected in CTLs, but there was accumulation of IRS2 in rapamycintreated CTLs, a result confirmed by immunoblot analysis (Fig. 4i) .
In terms of signaling molecules, mTORC1 activity was needed to sustain expression of the transcription factor NFIL3 and the phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P 3 ) phosphatase PTEN (reported below). mTORC1 was also needed for the expression of glucose transporters and enzymes that control glycolysis (Fig. 5a) , cholesterol-biosynthesis enzymes (Fig. 5b) , and cytosolic aminoacyl-tRNA synthetases and cytosolic ribosomal subunits (Fig. 5c) . Conversely, inhibition of mTORC1 increased the expression of CTL protein subsets, including (Fig. 5d) , mitochondrial aminoacyl-tRNA synthetases and ribosomes (Fig. 5e) , and the guanineexchange factor DOCK1 (data not shown). mTORC1 was thus able to both positively regulate and negatively regulate the expression of a subset of CTL proteins and its role was selective and cell specific.
Control of transcriptomes versus proteomes by mTORC1 mTORC1 controls expression of the transcription factors SREBP1, SREBP2 and HIF-1α 12, 13 . We thus used Affymetrix microarray analysis to assess the full extent of transcriptional changes caused by inhibition of mTORC1 and detected a total of 8,198 expressed transcripts (Fig. 6a) . Treatment with rapamycin decreased the expression of 226 mRNA transcripts and increased the expression of 220 mRNA transcripts in CTLs (Fig. 6a) . There was a strong correlation between the effect of mTORC1 inhibition on transcript abundance and its effect on protein abundance, for glucose transporters, glycolytic enzymes, cholesterol biosynthesis enzymes, granzymes, perforin and IFN-γ ( Fig. 6b-d) . However, of the 413 proteins whose expression was downregulated in the rapamycin-treated CTLs, only 95 showed a corresponding change in transcript abundance (Fig. 6b-d) . Similarly, of the 427 proteins upregulated, only 83 showed an increased abundance of mRNA transcripts (data not shown). Inhibition of mTORC1 thus regulated the expression of cytoplasmic and mitochondrial subunits of ribosomal complexes, oxidative phosphorylation enzymes and proteins encoded by mRNA transcripts with a 5′-terminal oligopyrimidine motif 10 at the protein level but not at the transcript level (Fig. 6e-g ). Furthermore, treatment of CTLs with rapamycin regulated the expression of IRS2, DOCK1, and PTEN at the protein level but not at the mRNA level (data not shown), which highlighted the importance of direct proteomic analysis for cell phenotyping. (Fig. 4d) compared with the frequency of these proteins in the total data set (darker color intensity indicates the P value is below the threshold of 0.05). (a-c) Downregulated expression of proteins involved in glycolysis and glucose transporters (including GLUT1 and GLUT3) (a), terpenoid backbone and steroid biosynthesis (including the rate-limiting enzyme HMGCR) (b), and cytoplasmic subunits of ribosomes ((cyto) ribosom) and aminoacyl-tRNA biosynthesis ((cyto) aa-tRNA) (c). 
Selective programming of CTL metabolism by mTORC1
Our data showed that only a small subclass of metabolic pathways, notably steroid-biosynthesis and glycolytic pathways, were controlled by mTORC1 in CTLs. CTLs express at least 72 nutrient transporters, but only 6 of these were regulated by mTORC1 (Fig. 7a) , which highlighted the selectivity of mTORC1's control of T cell metabolism. In particular, inhibition of mTORC1 did not prevent the expression of SLC1A5 (ASCT2), the key glutamine transporter in T cells 28 (Fig. 7a) , or decrease the expression of enzymes that regulate glutamine metabolism (Supplementary Fig. 2) . Indeed there was increased expression of some enzymes that control glutaminolytic reactions (for example, GLUD1) in CTLs in which mTORC1 was inhibited (Fig. 7b) . We assessed the relevance of these changes by measuring glutaminolysis activity and found a higher glutaminolytic rate in CTLs in which mTORC1 was inhibited (Fig. 7c) .
Another example of mTORC1's selectivity was that rapamycin caused a loss of glycolytic enzymes but increased expression of oxidative phosphorylation enzymes (Fig. 7d) . The ability of rapamycin to increase the expression of oxidative phosphorylation enzymes was consistent with the ability of rapamycin to promote the development of memory CD8 + T cells 7 that are dependent on oxidative phosphorylation rather than glycolysis 29 . The changes in the expression of glycolytic enzymes were significant and systematic, albeit not large (Fig.  7d) . Inhibition of mTORC1 thus decreased the expression of various glycolytic enzymes, but these enzymes were still abundant. 8% of the proteome of CTLs treated with the mTORC1 inhibitor thus consisted of glycolytic enzymes (Fig. 7e) . Furthermore, the quartile of the CTL proteome with the greatest protein abundance still showed enrichment for glycolytic enzymes even after prolonged inhibition of mTORC1 (Fig. 7f) . We then measured glycolysis and oxygen-consumption rates of DMSO-and rapamycin-treated CTLs. We assessed the cells in the basal state and after the addition of oligomycin (to block ATP synthesis), DNP (to uncouple ATP synthesis from the electron-transport chain), and antimycin A plus rotenone (to block electron-transport-chain complexes) to assess the spare respiratory capacity of mitochondria. The baseline data showed that CTLs consumed oxygen (Fig. 7g) and were glycolytic, as judged by their extracellular acidification rate (Fig. 7h) . There was no difference between DMSO-treated CTLs and rapamycin-treated CTLs in their baseline oxygen consumption or spare respiratory capacity (Fig. 7g) . However, rapamycin-treated CTLs had a decreased rate of extracellular acidification (Fig. 7h) , which reflected the fact that these cells have reduced rates of lactate output, an indicator of their glycolytic activity. They do not, however, show full ablation of lactate production. These metabolic data confirmed the prediction from the proteomic data that CTLs undertake oxidative phosphorylation and glycolysis and that mTORC1 modulates glycolysis in CTL.
We sought to determine the main cause of the decreased glycolysis in CTLs treated with the mTORC1 inhibitor, given that these cells retained abundant expression of glycolytic enzymes. One important factor in this is that glucose transporters supply the glucose that fuels both oxidative phosphorylation and glycolysis. CTLs expressed 62 × 10 3 molecules of GLUT1 and 73 × 10 3 molecules of GLUT3, and this abundance decreased to 36 × 10 3 and 48 × 10 3 , respectively, in CTLs treated with the mTORC1 inhibitor, which correlated with a twofold difference in glucose uptake (Fig. 7i) . In this context, the rate of lactate output in CTLs was very sensitive to a reduction in npg r e s o u r c e the supply of glucose (Fig. 7j) , which indicated that a diminished glucose supply, not the loss of glycolytic enzymes, limited glycolysis in the rapamycin-treated CTLs. The decreased glucose uptake in CTLs in which mTORC1 was inhibited would explain the lack of a detectable increase in oxidative phosphorylation associated with their increased expression of oxidative phosphorylation enzymes.
mTORC1 restrains PI(3)K-Akt signaling in CTL
We consistently saw downregulation in the expression of PTEN protein in rapamycin-treated CTLs, and this finding was confirmed by immunoblot analysis (Fig. 8a) . PTEN dephosphorylates PtdIns(3,4,5)P 3 , and this loss of PTEN raised the possibility that mTORC1 signaling normally restrains cellular accumulation of this lipid. We explored this directly and found that CTLs had a density of approximately 30 × 10 3 molecules of PtdIns(3,4,5)P 3 per cell (Fig. 8b) . Inhibition of the phosphatidylinositol-3-OH kinase (PI(3)K) catalytic subunit p110δ resulted in depletion of PtdIns(3,4,5)P 3 , but treatment with rapamycin increased the abundance of cellular PtdIns(3,4,5)P 3 (more than 60 × 10 3 molecules of PtdIns(3,4,5)P 3 per CTL after sustained inhibition of mTORC1; Fig. 8b ). PtdIns(3,4,5)P 3 binds to the plextrin homology (PH) domain of Akt, which allows the kinase PDK1 to phosphorylate Akt at Thr308 and thereby activate the enzyme 30 . Rapamycin-treated CTLs had more Akt phosphorylated at Thr308 than did untreated CTLs (Fig. 8c) , and this phosphorylation was lost when the rapamycin-treated CTLs were treated with an inhibitor of p110δ (Fig. 8d) or with the inhibitor AKTi1/2 (Fig. 8e) , which prevents binding of PtdIns(3,4,5)P 3 the Akt PH domain 31 . The increased abundance of PtdIns(3,4,5)P 3 in rapamycin-treated CTLs thus increased Akt activity, which showed that mTORC1 activity limited Akt function in CTLs.
Many signaling models position mTOR as a positive regulator of Akt. This is because mTORC2 can phosphorylate Akt at Ser473 (ref. 32) and thus create a docking site for the PDK1-interacting fragment (PIF) pocket of PDK1, which promotes efficient phosphorylation of Akt at Thr308 by PDK1 and activates the enzyme 33 . In this context, Rictor-deficient T cells, which lack mTORC2, have less the phosphorylation of Akt at Ser473 and Thr308 than that of T cells with functional mTORC2 signaling, which indicates that the docking of Akt phosphorylated at Ser473 to the PIF pocket of PDK1 can control Akt activity in T cells 34 . However, PDK1 contains a PtdIns(3,4,5)P 3 -binding PH domain, and PtdIns(3,4,5)P 3 -mediated co-localization of Akt and PDK1 can occur, which makes activation of Akt independent of its phosphorylation at Ser473 (ref. 35) .
The mTOR catalytic inhibitor KU-0063794 was as effective as rapamycin in blocking mTORC1 activity and downregulating the expression of PTEN (Fig. 8f) . KU-0063794 also caused CTLs to accumulate PtdIns(3,4,5)P 3 ( Fig. 8g) . High levels of PtdIns(3,4,5)P 3 might switch the balance between the regulation of Akt activity by the PIF pocket-dependent mechanism for the activation of Akt and the use of a PDK1 PH domain-dependent mechanism. In this context, integrity of the PDK1 PH domain is needed for optimal activation of Akt in CTLs 36 . Therefore, to address the role of Akt activation dependent on mTORC2 and the PIF pocket in CTLs, we assessed the effect of KU-0063794 on Akt in CTLs over an 18-hour period. KU-0063794 caused a rapid and sustained loss of mTORC1 activity and mTORC2-mediated phosphorylation of Akt at Ser473 (Fig. 8h) . The effect of KU-0063794 on the phosphorylation of Akt at Thr308, however, was biphasic (Fig. 8h) . The rapid de-phosphorylation of Akt at Ser473 in KU-0063794-treated cells was thus initially accompanied by de-phosphorylation of Akt at Thr308 and loss of Akt catalytic activity, as monitored by the loss of phosphorylation of the Akt substrates Thr24 in Foxo1 and Thr32 in Foxo3A (Fig. 8h) . Hence, treatment of CTLs with the catalytic inhibitor of mTOR caused rapid npg r e s o u r c e loss of Akt activity. However, the loss of phosphorylation of Akt at Thr308 in KU-0063794-treated CTLs was transient, and this phosphorylation was restored after approximately 6 h of treatment with KU-0063794 (Fig. 8h) . This re-phosphorylation was paralleled by restoration of Akt activity, as judged by corresponding re-phosphorylation of Foxo1 at Thr24 and of Foxo3A at Thr32 (Fig. 8h) . At the 18-hour time point, the phosphorylation of Akt at Thr308 and activity of Akt were enhanced compared with that of untreated CTLs, despite the absence of any detectable phosphorylation of Akt at Ser473 (Fig. 8h) . Akt's activity in CTLs was thus normally dependent on mTORC2-mediated phosphorylation of Akt at Ser473. However, in CTLs treated with the mTOR inhibitor KU-0063794, there was a reprogramming event, such that Akt's activity became independent of mTORcontrolled phosphorylation of Akt at Ser473. The importance of phosphorylation of Akt at Ser473 in T cells thus depended on the cellular concentration of PtdIns(3,4,5)P 3 . If this was high, then phosphorylation of Akt at Ser473 was not required for its phosphorylation at Thr308 or its catalytic activity (Supplementary Fig. 3) . The results reported above indicated that mTORC1's control of PtdIns(3,4,5)P 3 dominated mTORC2's control of Akt in CTLs, such that catalytic inhibitors of mTOR did not effectively disrupt Akt's activity. In this context, inhibition of Akt in CTLs causes re-expression of Foxo-regulated genes 37 . However, there was no re-expression of Foxoregulated genes in KU-0063794-treated CTLs ( Table 2) , in support of the conclusion that mTOR inhibitors did not disrupt Akt signaling in CTLs. Moreover, we found no difference in the transcriptional changes induced in CTLs by inhibition of mTORC1 with rapamycin versus those induced by catalytic inhibition of mTOR with KU-0063794 (Fig. 8i) .
Comparison of the effects of rapamycin and those of KU-0063794 on the CTL proteome by quantitative MS also found no major difference between these effects (Supplementary Fig. 4) . Hence, the catalytic inhibitor of mTOR blocked the activity of mTORC1 and mTORC2, but there was no discernable additional (on-or off-target) effect of this inhibitor on the T cells compared with the loss of mTORC1 activity alone. All proteomic data presented are available in the online, searchable Encyclopedia of Proteome Dynamics database to maximize accessibility to the scientific community (Supplementary Fig. 5 ).
DISCUSSION
In this study we have characterized the CTL proteome, mapping the abundance and expression of isoforms or orthologs of more than 6,800 proteins. These proteomic data are available in the Encyclopedia of Proteome Dynamics database. The abundance of some CTL proteins was striking: granzymes constituted collectively 1-2% of the CTL proteome, and glycolytic enzymes constituted 9% of the CTL proteome. The threshold of molecules needed for function is often unknown, but there is undoubtedly a new perspective in considering the biological relevance of changes in protein expression when protein abundance is factored into the equation. For example, a 100-fold decrease in the expression of granzyme B and perforin would reduce the density of granzyme B to ~1 × 10 5 copies per CTL and would reduce the density of perforin to approximately ~1 × 10 2 copies per CTL, a case in which granzyme B would still be abundant, whereas perforin would seem limiting. In another example, CD25 (IL-2 receptor α-chain) is expressed at an excess of ~100-fold relative to the IL-2 receptor β-chain and γ c subunit. The expression of CD25 could thus decrease tenfold without affecting expression of the high-affinity IL-2 receptor. Knowledge of protein copy number is thus invaluable information for full understanding of cell function. Information about the expression of protein isoforms can also provide new ideas about cellular control mechanisms. For example, CTLs express isoforms M1 and M2 of pyruvate kinase (PKM1 and PKM2). However, PKM2 dominates in terms of abundance, at >1 × 10 7 copies per CTL, versus <1 × 10 5 copies per CTL for PKM1. The PKM1 and PKM2 isoforms both use phosphoenolpyruvate as a substrate during glycolysis, but PKM2 can also function as a kinase for STAT3 and the kinase MEK5 (ref. 38) and is a co-activator of HIF-1α-mediated transcription 39 . The quantity of PKM2 in CTLs (>1 × 10 7 molecules per cell) permits this enzyme to serve multiple roles as a transcriptional and metabolic regulator.
One key insight here was that mTORC1 was not a global regulator of protein output in CTLs but instead selectively shaped the CTL proteome by controlling the expression of a small (<10%) subset of metabolic, effector and adhesion molecules that define CTL identity. mTORC1 repressed and stimulated the expression of equal numbers of proteins, which indicated that it simultaneously controlled protein production and protein degradation. The selectivity of mTORC1's control of the CTL proteome was notable, as was the finding that there was no considerable difference in CTLs in which mTORC1 alone was inhibited versus those with combined inhibition of mTORC1 and mTORC2. This suggested dominant role for mTORC1 in CTLs, compared with that of mTORC2. Genetic strategies that selectively delete either mTORC1 or mTORC2 have shown very different roles for these two complexes in T cells 8 . In particular, loss of mTORC2 complexes as a consequence of deletion of Rictor prevents phosphorylation of Akt at Ser473 and regulates Akt-mediated exclusion of Foxo transcription factors from the nucleus. We found that mTORC2 did control phosphorylation of Akt at Ser473 in T cells. However, we also discovered that mTORC1 repressed the accumulation of PtdIns(3,4,5)P 3 in CTLs. Specific inhibitors of mTORC1 and mTOR thus cause CTLs to accumulate very high levels of PtdIns(3,4,5)P 3 and reprogram their regulation of Akt such that activation of Akt becomes independent of the phosphorylation of Akt at Ser473 and thus becomes independent of mTORC2 activity. These results indicate that the biological effect of the combined catalytic inhibition of mTORC1 and mTORC2 cannot be predicted from genetic modifications that individually disrupt mTORC1 or mTORC2 complexes. In this context, although published studies have reported feedback control of Akt by mTORC1 in non-lymphoid cells [14] [15] [16] , the magnitude of the potentiation of PtdIns(3,4,5)P 3 levels in T cells by rapamycin, an immunosuppressant, was notable and was not an intuitive result, because PtdIns(3,4,5)P 3 is normally thought of as a positive regulator of T cells. However, constitutive activation of the PI(3)K catalytic subunit p110δ in humans results in an immunodeficiency syndrome (activated PI(3)Kδ syndrome). Hence, hyper-activation of PtdIns(3,4,5)P 3 signaling pathways in T cells is effectively immunosuppressive 40, 41 . The 'hyper-production' of PtdIns(3,4,5)P 3 might be part of the mechanism whereby inhibitors of mTORC1 suppress T cell immunity. Our study has thus demonstrated the power of unbiased proteomic analysis in generating new understanding of the mechanisms of drug action.
Published studies have suggested that mTORC1 phosphorylates and targets for degradation GRB10, a negative regulator of PI(3)K 14, 15 . We found that GRB10 was not expressed in CTLs. However, mTORC1 controls the expression of PTEN, another key negative regulator of PI(3)K pathways. In this context, it has been reported that Microarray analysis of transcript intensity in CTLs treated with rapamycin, KU-0063794 or AKTi1/2 relative to that in untreated cells. AKTi1/2 data obtained from a published study 37 .
npg mTORC1-mediated phosphorylation and degradation of the adaptor IRS2 acts to restrain Akt activity in non-lymphoid cells 16 . We showed here that mTORC1 controlled the amount of IRS2 in T cells and controlled another key adaptor, DOCK1. In this context, the increased expression of DOCK1 and IRS2 in rapamycin-treated CTLs indicated that inhibition of mTORC1 would promote the signaling pathways controlled by these molecules. mTOR thus has cell type-specific actions, and full understanding of its role it will require analysis of its function in different leucocyte populations.
METhODS
Methods and any associated references are available in the online version of the paper.
